{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:44:43Z","timestamp":1762875883080},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.endinu.2017.04.005","type":"journal-article","created":{"date-parts":[[2017,6,4]],"date-time":"2017-06-04T03:01:01Z","timestamp":1496545261000},"page":"341-344","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibidores de proprote\u00edna convertasa subtilisina\/kexina tipo 9 (iPCSK9). Los nuevos de la clase en el tratamiento de la hipercolesterolemia"],"prefix":"10.1016","volume":"64","author":[{"given":"Emilio","family":"Ortega Mart\u00ednez de Victoria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.endinu.2017.04.005_bib0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpt.281","article-title":"Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids","volume":"99","author":"Shantha","year":"2016","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"10.1016\/j.endinu.2017.04.005_bib0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet."},{"issue":"6","key":"10.1016\/j.endinu.2017.04.005_bib0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.endonu.2016.02.002","article-title":"Inhibition of proprotein convertase subtilisin\/kexin type 9 in the treatment of hypercholesterolemia","volume":"63","author":"Ascaso","year":"2016","journal-title":"Endocrinol y Nutr (English Ed.)"},{"issue":"3","key":"10.1016\/j.endinu.2017.04.005_bib0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.recesp.2015.11.016","article-title":"M\u00e1xima reducci\u00f3n de colesterol unido a lipoprote\u00ednas de baja densidad alcanzable con combinaciones farmacol\u00f3gicas. Cuando 50 m\u00e1s 20 suma 60","volume":"69","author":"Masana","year":"2016","journal-title":"Rev Espa\u00f1ola Cardiol."},{"issue":"3","key":"10.1016\/j.endinu.2017.04.005_bib0150","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jacl.2016.02.003","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial","volume":"10","author":"Moriarty","year":"2016","journal-title":"J Clin Lipidol."},{"issue":"5","key":"10.1016\/j.endinu.2017.04.005_bib0155","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.endinu.2017.04.005_bib0160","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.endinu.2017.04.005_bib0165","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J."},{"issue":"15","key":"10.1016\/j.endinu.2017.04.005_bib0170","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of Evolocumab vs Ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA."},{"issue":"14","key":"10.1016\/j.endinu.2017.04.005_bib0175","first-page":"1425","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients","volume":"352","author":"Nicholls","year":"2016","journal-title":"JAMA."},{"issue":"15","key":"10.1016\/j.endinu.2017.04.005_bib0180","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1 HMGCR, or Both: A 2 \u00d7 2 Factorial mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"10.1016\/j.endinu.2017.04.005_bib0185","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA."},{"issue":"22","key":"10.1016\/j.endinu.2017.04.005_bib0190","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: A quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"10.1016\/j.endinu.2017.04.005_bib0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.arteri.2016.02.001","article-title":"Documento de consenso de la Sociedad Espa\u00f1ola de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9","volume":"28","author":"Masana","year":"2016","journal-title":"Cl\u00ednica e Investig en Arterioscler."},{"key":"10.1016\/j.endinu.2017.04.005_bib0200","unstructured":"AEMPS. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios - Medicamentos de uso humano - Informes de posicionamiento terap\u00e9utico. [consultado 18 Abr 2017]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/home.htm#hiperlipemias."},{"key":"10.1016\/j.endinu.2017.04.005_bib0205","unstructured":"CatSalut. Informes i dict\u00e0mens. CatSalut. Servei Catal\u00e0 de la Salut. [consultado 18 Abr 2017]. Disponible en: http:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/farmacia-medicaments\/avaluacio-harmonitzacio-farmacoterapeutica\/phf-mhda\/informes\/"},{"issue":"1","key":"10.1016\/j.endinu.2017.04.005_bib0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCOUTCOMES.112.967893","article-title":"Cardiovascular health in a southern mediterranean european country a nationwide population-based study","volume":"6","author":"Graciani","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"45","key":"10.1016\/j.endinu.2017.04.005_bib0215","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.endinu.2017.04.005_bib0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2016.03.023","article-title":"Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins","volume":"249","author":"Rallidis","year":"2016","journal-title":"Atherosclerosis."},{"issue":"7","key":"10.1016\/j.endinu.2017.04.005_bib0225","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med."},{"issue":"40","key":"10.1016\/j.endinu.2017.04.005_bib0230","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.2174\/1381612820666140620162629","article-title":"Statin treatment non-adherence and discontinuation: clinical implications and potential solutions","volume":"20","author":"Phan","year":"2014","journal-title":"Curr Pharm Des."},{"issue":"10059","key":"10.1016\/j.endinu.2017.04.005_bib0235","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2017","journal-title":"Lancet."},{"issue":"16","key":"10.1016\/j.endinu.2017.04.005_bib0240","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.endinu.2017.04.005_bib0245","doi-asserted-by":"crossref","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term low-density lipoprotein cholesterol\u2013lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label osler-1 extension study. JAMA Cardiol. 2017.","DOI":"10.1001\/jamacardio.2017.0747"},{"issue":"2","key":"10.1016\/j.endinu.2017.04.005_bib0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/clc.22678","article-title":"Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin backgroun","volume":"40","author":"Giugliano","year":"2017","journal-title":"Clin Cardiol"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016417301453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016417301453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T22:53:02Z","timestamp":1636239182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016417301453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S2530016417301453"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2017.04.005","relation":{},"ISSN":["2530-0164"],"issn-type":[{"value":"2530-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibidores de proprote\u00edna convertasa subtilisina\/kexina tipo 9 (iPCSK9). Los nuevos de la clase en el tratamiento de la hipercolesterolemia","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2017.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEEN y SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}